Skip to main content
Log in

Testing for Tetrahydrobiopterin Responsiveness in Patients with Hyperphenylalaninemia due to Phenylalanine Hydroxylase Deficiency

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Pharmacological levels of the phenylalanine hydroxylase enzyme cofactor, tetrahydrobiopterin (BH4), reduce plasma phenylalanine levels in some patients with phenylketonuria (PKU), providing the first pharmacological therapy for PKU. Responsiveness to this therapy must be determined empirically through a BH4 loading test or trial. The authors have analyzed the loading tests currently in use in light of the numerous factors that can influence their results. Sapropterin dihydrochloride is a stable, synthetic form of BH4 approved for treatment of PKU in responsive patients.

Methods

An expert panel identified evidence from published reports of clinical experience. Reports of research involving at least 25 patients and published in English were considered.

Results

In all, 14 studies met both criteria; eight employing the sapropterin dihydrochloride preparation from Schircks Laboratories and six the sapropterin dihydrochloride preparation from Biomarin/Merck Serono.

Conclusion

The arbitrary responsiveness definition of a >30% reduction in blood phenylalanine appears to be a good compromise between sensitivity and specificity for the initial screening test. However, individual patient characteristics should be considered when interpreting results, especially in patients with low baseline phenylalanine levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pangkanon S, Charoensiriwatana W, Janejai N, Boonwanich W, Chaisomchit S. Detection of phenylketonuria by the newborn screening program in Thailand. Southeast Asian J Trop Med Public Health. 2009;40:525–529.

    PubMed  CAS  Google Scholar 

  2. Ozgüç M, Ozalp I, Coškun T, Yilmaz E, Erdem H, Ayter S. Mutation analysis in Turkish phenylketonuria patients. J Med Genet. 1993;30:129–130.

    Article  PubMed  Google Scholar 

  3. Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011;104(Suppl.):S2–S9.

    Article  PubMed  CAS  Google Scholar 

  4. Italian Society for the Study of Hereditary Metabolic Diseases and Newborn Screening (SIMMESN). Annual technical report. 2010. Available at: http://www.sismme.it/it/documents/rt_screening/rt_screening_2010.pdf. Accessed Feb 4 2013.

  5. Kure S, Hou DC, Ohura T, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr. 1999;135:375–378.

    Article  PubMed  CAS  Google Scholar 

  6. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417–1427.

    Article  PubMed  CAS  Google Scholar 

  7. Burton BK, Grange DK, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis. 2007;30:700–707.

    Article  PubMed  CAS  Google Scholar 

  8. Levy HL, Milanowski A, Chakrapani A, et al.; Sapropterin Research Group. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007;370:504–510.

    CAS  Google Scholar 

  9. Trefz FK, Burton BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr. 2009;154:700–707.

    Article  PubMed  CAS  Google Scholar 

  10. Cazzorla C, Del Rizzo M, Burgard P, et al. Application of the WHOQOL-100 for the assessment of quality of life of adult patients with inherited metabolic diseases. Mol Genet Metab. 2012;106:25–30.

    Article  PubMed  CAS  Google Scholar 

  11. Bélanger-Quintana A, Burlina A, Harding CO, Muntau AC. Up to date knowledge on different treatment strategies for phenylketonuria. Mol Genet Metab. 2011;104(Suppl.):S19–S25.

    Article  PubMed  Google Scholar 

  12. Singh RH, Quirk ME. Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria. Mol Genet Metab. 2011;104:485–491.

    Article  PubMed  CAS  Google Scholar 

  13. Lee P, Treacy EP, Crombez E, et al.; Sapropterin Research Group. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A. 2008;146A:2851–2859.

    Article  PubMed  CAS  Google Scholar 

  14. Aguado C, Pérez B, García MJ, et al. BH4 responsiveness associated to a PKU mutation with decreased binding affinity for the cofactor. Clin Chim Acta. 2007;380:8–12.

    Article  PubMed  CAS  Google Scholar 

  15. Pey AL, Stricher F, Serrano L, Martinez A. Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am J Hum Genet. 2007;81:1006–1024.

    Article  PubMed  CAS  Google Scholar 

  16. Gersting SW, Kemter KF, Staudigl M, et al. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am J Hum Genet. 2008;83:5–17.

    Article  PubMed  CAS  Google Scholar 

  17. Levy H, Burton B, Cederbaum S, Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol Genet Metab. 2007;92:287–291.

    Article  PubMed  CAS  Google Scholar 

  18. Blau N, Bélanger-Quintana A, Demirkol M, et al. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol Genet Metab. 2009;96:158–163.

    Article  PubMed  CAS  Google Scholar 

  19. Gordon P, Thomas JA, Suter R, Jurecki E. Evolving patient selection and clinical benefit criteria for sapropterin dihydrochloride (Kuvan PKU patients. Mol Genet Metab. 2012;105:672–676.

    Article  PubMed  CAS  Google Scholar 

  20. Blau N, Bélanger-Quintana A, Demirkol M, et al.; European PKU Centers. Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab. 2010;99:109–115.

    CAS  Google Scholar 

  21. Bueno MA, Lage S, Delgado C, et al. New evidence for assessing tetrahydrobiopterin (BH(4)) responsiveness. Metabolism. 2012;61:1809–1816.

    Article  PubMed  CAS  Google Scholar 

  22. Desviat LR, Pérez B, Bèlanger-Quintana A, et al. Tetrahydrobiopterin responsiveness: results of the BH4 loading test in 31 Spanish PKU patients and correlation with their genotype. Mol Genet Metab. 2004;83:157–162.

    Article  PubMed  CAS  Google Scholar 

  23. Fiege B, Blau N. Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J Pediatr. 2007;150:627–630.

    Article  PubMed  CAS  Google Scholar 

  24. Fiori L, Fiege B, Riva E, Giovannini M. Incidence of BH4-responsiveness in phenylalanine-hydroxylasedeficient Italian patients. Mol Genet Metab. 2005;86(Suppl. 1):S67–S74.

    Article  PubMed  CAS  Google Scholar 

  25. Leuzzi V, Carducci C, Carducci C, et al. The spectrum of phenylalanine variations under tetrahydrobiopterin load in subjects affected by phenylalanine hydroxylase deficiency. J Inherit Metab Dis. 2006;29:38–46.

    Article  PubMed  CAS  Google Scholar 

  26. Matalon R, Michals-Matalon K, Koch R, Grady J, Tyring S, Stevens RC. Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Mol Genet Metab. 2005;86(Suppl. 1):S17–S21.

    Article  PubMed  CAS  Google Scholar 

  27. Mitchell JJ, Wilcken B, Alexander I, et al. Tetrahydrobiopterin-responsive phenylketonuria: the New South Wales experience. Mol Genet Metab. 2005;86(Suppl. 1):S81–S85.

    Article  PubMed  CAS  Google Scholar 

  28. Pérez-Dueñas B, Vilaseca MA, Mas A, et al. Tetrahydrobiopterin responsiveness in patients with phenylketonuria. Clin Biochem. 2004;37:1083–1090.

    Article  PubMed  Google Scholar 

  29. Anjema K, Venema G, Hofstede FC, et al. The 48- hour tetrahydrobiopterin loading test in patients with phenylketonuria: evaluation of protocol and influence of baseline phenylalanine concentration. Mol Genet Metab. 2011;104(Suppl.):S60–S63.

    Article  PubMed  CAS  Google Scholar 

  30. Utz JR, Lorentz CP, Markowitz D, et al. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. Mol Genet Metab. 2012;105:193–197.

    Article  PubMed  CAS  Google Scholar 

  31. Vernon HJ, Koerner CB, Johnson MR, Bergner A, Hamosh A. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria. Mol Genet Metab. 2010;100:229–233.

    Article  PubMed  CAS  Google Scholar 

  32. Enns GM, Koch R, Brumm V, Blakely E, Suter R, Jurecki E. Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab. 2010;101:99–109.

    Article  PubMed  CAS  Google Scholar 

  33. Hanley WB. Non-PKU mild hyperphenylalaninemia (MHP) - the dilemma. Mol Genet Metab. 2011;104:23–26.

    Article  PubMed  CAS  Google Scholar 

  34. van Spronsen FJ. Mild hyperphenylalaninemia: to treat or not to treat. J Inherit Metab Dis. 2011;34:651–656.

    Article  PubMed  Google Scholar 

  35. Michals K, Azen C, Acosta BP, Koch R, Matalon R. Blood phenylalanine and intelligence of tenyear- old children with phenylketonuria in the national collaborative study. J Am Diet Assoc. 1998;88:1226–1229.

    Google Scholar 

  36. Holtzman N, Kronmal RA, van Doornick W, Azen C, Koch R. Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria. N Engl J Med. 1986;34: 593–598.

    Article  Google Scholar 

  37. Shintaku H, Kure S, Ohura T, et al. Long-term treatment and diagnosis of tetrahydrobiopterinresponsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatr Res. 2004;55:425–430.

    Article  PubMed  CAS  Google Scholar 

  38. Cunningham A, Bausell H, Brown M, et al. Recommendations for the use of sapropterin in phenylketonuria. Mol Genet Metab. 2012;106: 269–276.

    Article  PubMed  CAS  Google Scholar 

  39. Fiege B, Bonafé L, Ballhausen D, et al. Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Mol Genet Metab. 2005;86(Suppl. 1):S91–S95.

    Article  PubMed  CAS  Google Scholar 

  40. Zurflüh MR, Zschocke J, Lindner M, et al. Molecular genetics of tetrahydrobiopterinresponsive phenylalanine hydroxylase deficiency. Hum Mutat. 2008;29:167–175.

    Article  PubMed  Google Scholar 

  41. Dobrowolski SF, Heintz C, Miller T, et al. Molecular genetics and impact of residual in vitro phenylalanine hydroxylase activity on tetrahydrobiopterin responsiveness in Turkish PKU population. Mol Genet Metab. 2011;102:116–121.

    Article  PubMed  CAS  Google Scholar 

  42. Lambruschini N, Pérez-Dueñas B, Vilaseca MA, et al. Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab. 2005;86(Suppl. 1):S54–S60.

    Article  PubMed  CAS  Google Scholar 

  43. Ponzone A, Guardamagna O, Spada M, et al. Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test. Eur J Pediatr. 1993;152:655–661.

    Article  PubMed  CAS  Google Scholar 

  44. Ponzone A, Spada M, Roasio L, Porta F, Mussa A, Ferraris S. Impact of neonatal protein metabolism and nutrition on screening for phenylketonuria. J Pediatr Gastroenterol Nutr. 2008;46:561–569.

    Article  PubMed  Google Scholar 

  45. Burton BK, Adams DJ, Grange DK, et al. Tetrahydrobiopterin therapy for phenylketonuria in infants and young children. J Pediatr. 2011;158:410–415.

    Article  PubMed  CAS  Google Scholar 

  46. Bóveda MD, Couce ML, Castiñeiras DE, et al. The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: evaluation of response and subsequent treatment. J Inherit Metab Dis. 2007;30:812.

    Article  PubMed  Google Scholar 

  47. Hennermann JB, Bührer C, Blau N, Vetter B, Mönch E. Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol Genet Metab. 2005;86(Suppl. 1):S86–S90.

    Article  PubMed  CAS  Google Scholar 

  48. Spaapen LJ, Bakker JA, Velter C, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency in Dutch neonates. J Inherit Metab Dis. 2001;24:352–358.

    Article  PubMed  CAS  Google Scholar 

  49. Leuret O, Barth M, Kuster A, et al. Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria. J Inherit Metab Dis. 2012;35:975–981.

    Article  PubMed  CAS  Google Scholar 

  50. Prick BW, Hop WC, Duvekot JJ. Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies. Am J Clin Nutr. 2012;95:374–382.

    Article  PubMed  CAS  Google Scholar 

  51. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 449: Maternal phenylketonuria. Obstet Gynecol. 2009;114: 1432–1433.

    Google Scholar 

  52. Koch R, Hanley W, Levy H, et al. The Maternal Phenylketonuria International Study: 1984–2002. Pediatrics. 2003;112:1523–1529.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Roberto Cerone.

Additional information

To view enhanced content go to http://www.advancesintherapy.com

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cerone, R., Andria, G., Giovannini, M. et al. Testing for Tetrahydrobiopterin Responsiveness in Patients with Hyperphenylalaninemia due to Phenylalanine Hydroxylase Deficiency. Adv Therapy 30, 212–228 (2013). https://doi.org/10.1007/s12325-013-0011-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-013-0011-x

Keywords

Navigation